◎ Sugi Atlas

Atlas / Disease / Alcohol-related disorders

Alcohol-related disorders

disease
On this page

Also known as alcohol related disordersalcohol-related disorderdisorder, alcohol-relateddisorders, alcohol-related

Summary

Alcohol-related disorders (MONDO:0021698) is a disease (an umbrella term covering 8 Mondo subtypes) with 41 GWAS associations across 13 studies and 108 clinical trials. Top therapeutic interventions include fluoxetine, bupropion, and disulfiram. A subtype of substance-related disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 8 Mondo subtypes
  • GWAS associations: 41
  • Clinical trials: 108

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namealcohol-related disorders
Mondo IDMONDO:0021698
MeSHD019973
SNOMED CT29212009
UMLSC0236664
MedGen68632
Is cancer (heuristic)no

Also known as: alcohol related disorders · alcohol-related disorder · disorder, alcohol-related · disorders, alcohol-related

Data availability: 41 GWAS associations (13 studies).

Disease family

This is a subtype of substance-related disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › alcohol-related disorders

Related subtypes (3): substance abuse, substance dependence, substance withdrawal syndrome

Subtypes (8): alcohol abuse, alcoholic psychosis, alcohol withdrawal delirium, Wernicke encephalopathy, alcohol dependence, alcohol sensitivity, acute, alcohol-induced disorders, alcohol amnestic disorder

Genetics & variants

GWAS landscape

41 GWAS associations across 13 studies. Top hits map to 13 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs12299846e-239ADH1BT0.61
rs46467762e-74ALDH2?
rs20667022e-54ADH1BG0.18
rs131073252e-38SLC39A8C0.13
rs46659722e-27SNX17T0.06
chr2:451549083e-26G0.06
rs14210856e-23FTOT0.05
rs119406945e-22KLBA0.05
chr11:1133177456e-20G0.05
rs12603269e-19GCKRT0.05
rs71104403e-17DRD2 - TMPRSS5C0.05
rs116420155e-17FTOC0.05
rs130166652e-16ACTG1P22 - VRK2C0.05
chr2:1442043388e-16C0.04
chr3:494694498e-15G0.05
rs6713e-14ALDH2G0.73
rs64462623e-13RHOAT0.05
chr12:816024496e-13A0.04
rs570442141e-12ARID4A, TOMM20L-DTG0.04
rs79379341e-12SORL1 - RNU6-256PC0.04
chr7:1351704483e-12A0.04
chr10:106823193e-12A0.05
chr11:576546053e-12C0.04
chr11:1215429233e-12A0.04
rs839953e-12SIX3-AS1G0.04
chr10:1108011734e-12C0.04
chr8:574295836e-12A0.04
rs134059866e-12ARHGAP15A0.04
chr9:1278255051e-11T0.04
chr16:300160221e-11C0.04

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90079793Backman JD2021114,302230,584Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083779Backman JD2021114,302230,584Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90476520Verma A202479,529348,455Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476519Verma A202437,01777,731Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480768Verma A202437,01777,731Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90691955Karczewski KJ202516,070392,046Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects.
GCST90476517Verma A202414,83941,253Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90435890Zhou W201812,922379,355Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90651131Liu TY20252,311230,991Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90476518Verma A20247195,857Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding5
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic29

MAF distribution

BucketVariants
common (>=0.05)32
low_freq (0.01-0.05)1
rare (<0.01)1
unknown0

Functional consequences

ConsequenceCount
unknown15
intron_variant12
missense_variant5
intergenic_variant1
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs1229984499318162T>A,C,G0.037missense_variantADH1B6e-239Tier 1: coding
rs464677612111792215G>A,C0.05intron_variantALDH22e-74Tier 4: intronic/intergenic
rs2066702499307860G>A,C0.19missense_variantADH1B2e-54Tier 1: coding
rs131073254102267552C>A,T0.083missense_variantSLC39A82e-38Tier 1: coding
rs4665972227375230T>C0.415intron_variantSNX172e-27Tier 4: intronic/intergenic
chr2:451549080.4343e-26Tier 4: intronic/intergenic
rs14210851653767042T>C0.407intron_variantFTO6e-23Tier 4: intronic/intergenic
rs11940694439413373A>G0.423intron_variantKLB5e-22Tier 4: intronic/intergenic
chr11:1133177450.3786e-20Tier 4: intronic/intergenic
rs1260326227508073T>A,C,G0.356missense_variantGCKR9e-19Tier 1: coding
rs711044011113478652C>A0.312intergenic_variantDRD2 - TMPRSS53e-17Tier 4: intronic/intergenic
rs116420151653768582C>G,T0.329intron_variantFTO5e-17Tier 4: intronic/intergenic
rs13016665257768213C>A,T0.427intron_variantACTG1P22 - VRK22e-16Tier 4: intronic/intergenic
chr2:1442043380.3598e-16Tier 4: intronic/intergenic
chr3:494694490.268e-15Tier 4: intronic/intergenic
rs67112111803962G>A0.005missense_variantALDH23e-14Tier 1: coding
rs6446262349363720T>C0.238intron_variantRHOA3e-13Tier 4: intronic/intergenic
chr12:816024490.4846e-13Tier 4: intronic/intergenic
rs570442141458367191G>A,C,T0.269intron_variantARID4A, TOMM20L-DT1e-12Tier 4: intronic/intergenic
rs793793411121764503C>A,T0.369intron_variantSORL1 - RNU6-256P1e-12Tier 4: intronic/intergenic
chr7:1351704480.4043e-12Tier 4: intronic/intergenic
chr10:106823190.2023e-12Tier 4: intronic/intergenic
chr11:576546050.3323e-12Tier 4: intronic/intergenic
chr11:1215429230.4623e-12Tier 4: intronic/intergenic
rs83995244940431G>T0.329non_coding_transcript_exon_variantSIX3-AS13e-12Tier 4: intronic/intergenic
chr10:1108011730.3244e-12Tier 4: intronic/intergenic
chr8:574295830.2536e-12Tier 4: intronic/intergenic
rs134059862143404165A>G0.297intron_variantARHGAP156e-12Tier 4: intronic/intergenic
chr9:1278255050.3021e-11Tier 4: intronic/intergenic
chr16:300160220.481e-11Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Disulfiram, Melatonin, Naltrexone, Nitrous Oxide, Sevoflurane.

Clinical trials & evidence

Clinical trials

Clinical trials: 108.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified72
PHASE212
PHASE112
PHASE44
PHASE34
PHASE2/PHASE32
PHASE1/PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00061113PHASE4COMPLETEDSubstance Dependent Teens - Impact of Treating Depression Study 1 - 1
NCT00145847PHASE4COMPLETEDNaltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00402571PHASE4COMPLETEDHepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics
NCT00427206PHASE4COMPLETEDHepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing
NCT07039175PHASE3RECRUITINGIntervention to Increase Intention to Change Alcohol/Tobacco Use in Veterans With Chronic Disease
NCT00202514PHASE2/PHASE3COMPLETEDPlacebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms
NCT00248612PHASE2/PHASE3COMPLETEDPsychosocial and Medication Treatment for Anxiety in Alcoholism
NCT00304707PHASE3COMPLETEDEffectiveness of Bupropion for Smokers Recovering From Alcohol Dependence
NCT00444418PHASE3COMPLETEDMedication and Counseling for Controlled Drinking (Project SMART)
NCT01573416PHASE3COMPLETEDEffectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care.
NCT00000261PHASE2COMPLETEDEffects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13
NCT00000278PHASE2COMPLETEDDisulfiram for Cocaine-Alcohol Abuse - 3
NCT00000307PHASE2COMPLETEDNaltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4
NCT00106106PHASE2COMPLETEDAcamprosate to Reduce Symptoms of Alcohol Withdrawal
NCT00142818PHASE2COMPLETEDModafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence
NCT00142844PHASE2COMPLETEDCombination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
NCT00379093PHASE2COMPLETEDHealthy Living as You Age
NCT00861146PHASE2COMPLETEDConcurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk
NCT01227980PHASE2COMPLETEDCorticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^
NCT01631630PHASE2TERMINATEDRole of Proinflammatory Signaling in Alcohol Craving
NCT01847183PHASE2COMPLETEDEvaluation of an School-based Alcohol Prevention Program for Middle School Students
NCT02885311PHASE1/PHASE2COMPLETEDCollaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
NCT03043443PHASE2COMPLETEDMelatonin Use for Sleep Problems in Alcohol Dependent Patients
NCT05623501PHASE1NOT_YET_RECRUITINGPhase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease
NCT06070649PHASE1RECRUITINGThe Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
NCT06636227PHASE1RECRUITINGDiclofenac Dose Response Study
NCT00094289PHASE1UNKNOWNInteractions Between Cocaine and Ethanol and Disulfiram - 1
NCT00230100PHASE1COMPLETEDThe Women’s Recovery Group Study: Stage I Trial
NCT00946322PHASE1COMPLETEDCouple-Based Treatment for Alcohol Use Disorders and Post-Traumatic Stress Disorder
NCT01399554PHASE1COMPLETEDExercise as Alcohol Use Disorders Intervention for Non-Treatment Seeking Adults
NCT02039349PHASE1COMPLETEDA Novel Compound for Alcoholism Treatment
NCT02294266PHASE1COMPLETEDMephedrone and Alcohol Interactions in Humans
NCT02407340PHASE1COMPLETEDLaboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder
NCT02771587PHASE1COMPLETEDInteraction of Alcohol With Energy Drinks
NCT04210713PHASE1COMPLETEDNeuroimmune Dysfunction in Alcohol Use Disorder
NCT03497442EARLY_PHASE1COMPLETEDTreatment of Asian Flushing Syndrome With Topical Alpha Agonists
NCT02108080Not specifiedRECRUITINGCharacterization Imaging Instruments in Alcoholics and Non-Alcoholics
NCT04234139Not specifiedENROLLING_BY_INVITATIONCohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
NCT04391816Not specifiedRECRUITINGCOVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study
NCT04897295Not specifiedNOT_YET_RECRUITINGNeurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
FLUOXETINE44
BUPROPION43
DISULFIRAM43
FLUVOXAMINE43
NALTREXONE43
PRAZOSIN43
VENLAFAXINE43
ACETAMINOPHEN42
ALCOHOL42
DUTASTERIDE42
ACAMPROSATE41
BRIMONIDINE TARTRATE41
DIVALPROEX SODIUM41
MIRTAZAPINE41
MODAFINIL41
TRAZODONE41
PEPPERMINT OIL31
PEXACERFONT31
AMPELOPSIN21
MEBUFOTENIN21
PF-519045721
MEPHEDRONE11
CHEMBL541759103
CHEMBL542606401

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 19

This page pulls from 19 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpefogenccgwasgwas_studyhgncmedgenmeshmimmondomondochildmondoparentorphanetsctidumls